Precision Medicine News and Updates | Precision Medicine Online
WEBThe adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape future Phase III clinical trials. Three months after treatment with troculeucel, two patients in the Phase I portion went from having moderate to mild symptoms of dementia. Precision Medicine Online provides the latest news ...
Precision Oncology News - Precision Medicine Online
WEBSep 16, 2024. AI-Driven Genomic Test Shows Promise in De-Escalating Neoadjuvant TNBC Therapy. Sep 15, 2024. TORL BioTherapeutics' CLDN6-Targeting Antibody-Drug Conjugate Demonstrates Encouraging Early Results. Sep 15, 2024. Bristol Myers Squibb's Krazati Bests Chemo in KRAS-Mutant NSCLC With Brain Metastases. Sep 15, 2024.
Astellas' Vyloy Approved in Europe as First-Line Treatment for …
WEB5 hours ago · NEW YORK – The European Commission on Friday approved Astellas Pharma's Vyloy (zolbetuximab) plus chemo as a first-line treatment for patients with locally advanced, unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN)18.2 positive.
Disease Research & Diagnostics News | Precision Medicine Online
WEBNews and analysis on disease research and diagnostics from Precision Medicine Online.
Precision Medicine Diagnostics
WEBBioNexus Gene Lab, Shenzhen Rongguang Team up on Cancer Screening, Precision Medicine Programs. Sep 13, 2024. AbbVie's Telisotuzumab Vedotin Effective in NSCLC Patients With High, Intermediate c-MET Expression. Sep 12, 2024. Cancer Centers Look to New NGS-Based 'Frankenpanel' to Get Fast Info on Clinically Actionable Genes.
Breaking News - Precision Medicine Online
WEBSep 13, 2024 · Population Testing for BRCA1/2 Appears Cost-Effective in Younger Canadian Women. Using simulated data for 1 million women, researchers found that population-based BRCA1/2 testing would be cost-effective, particularly in 30-year-old women. Sep 13, 2024.
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd …
WEB5 hours ago · NEW YORK – In the Phase III TROPION-Breast01 clinical trial, patients with previously treated hormone receptor (HR)-positive, HER2-negative or -low breast cancer did not experience a statistically significant overall survival benefit from datopotamab deruxtecan (Dato-DXd) compared to chemotherapy, a finding that AstraZeneca and Daiichi Sankyo will share with regulators.
Precision Oncology in 2022: New Drugs and Tests Amid Ongoing …
WEBJan 4, 2023 · NEW YORK – Looking back at 2022, plenty of new CAR T-cell, radioligand, and biomarker-defined treatments entered the market, as did new tissue and liquid biopsy tests to identify cancer patients eligible for these therapies.
Autoimmune Disease Research News - Precision Medicine Online
WEBJun 20, 2024 · JW Therapeutics, 2seventy Bio Partner to Develop Cell Therapy for Autoimmune Diseases in China. News on research and diagnostics in autoimmune disorders including rheumatoid arthritis, lupus, multiple sclerosis, and more from Precision Medicine Online.
Disease Research for Precision Medicine | Precision Medicine Online
WEB4 days ago · Foundation Medicine, Syndax Pharmaceuticals Partner to Develop CDx for AML Treatment. Load More. Breaking News. News on disease research and therapeutic development trends in precision medicine from Precision Medicine Online.
Skip to content